Provigil and Diphenhydramine Interaction: What Clinicians and Patients Need to Know

Do modafinil and diphenhydramine work against each other?

Modafinil is approved to improve wakefulness in adults with excessive sleepiness from narcolepsy, obstructive sleep apnea or shift work disorder, at 200 mg once daily in the morning, or about an hour before a night shift for shift work disorder [2]. The label says the mechanism is unknown: modafinil binds the dopamine transporter and inhibits dopamine reuptake in vitro, its wakefulness effect can be attenuated by the alpha-1 blocker prazosin, and mice lacking the dopamine transporter showed no wake-promoting response [2]. In rats, modafinil activated neurons in the tuberomammillary nucleus and orexin neurons of the perifornical area, both regions tied to wakefulness [7].

Diphenhydramine is a first-generation H1 antihistamine. Its sedation is likely caused by blockade of excitatory H1 histamine receptors in the cerebral cortex, and it has additional anticholinergic (drying) effects [1].

The clearest human comparison gave each drug on its own. In a placebo-controlled, double-blind study, 16 healthy men received single doses of diphenhydramine 75 mg, modafinil 200 mg or placebo [1]. Diphenhydramine lowered critical flicker fusion frequency and alertness ratings and increased the pupillary fatigue indices; modafinil reduced those pupillary fatigue measures. Pupil diameter fell after diphenhydramine and rose after modafinil, salivation fell with diphenhydramine, and systolic blood pressure rose with modafinil. The investigators concluded that the two drugs produce opposite effects on arousal and sympathetic function [1].

Does modafinil change how diphenhydramine is broken down?

Modafinil acts on drug-metabolizing enzymes in two directions: it induces CYP3A4/5 and inhibits CYP2C19 [2]. The Provigil label gives specific examples: clearance of CYP3A4/5 substrates such as steroidal contraceptives, cyclosporine, midazolam and triazolam may increase, and elimination of CYP2C19 substrates such as phenytoin, diazepam, propranolol, omeprazole and clomipramine may be prolonged [2]. Diphenhydramine is not one of the drugs named in that section [2].

For diphenhydramine itself, a study using 14 recombinant P450 isozymes and human liver microsomes found that CYP2D6 had the highest activity for diphenhydramine N-demethylation at clinically relevant concentrations, with CYP1A2, CYP2C9 and CYP2C19 identified as low-affinity contributors [3].

The Provigil label adds that in people deficient in CYP2D6, levels of CYP2D6 substrates that are also cleared partly by CYP2C19, such as tricyclic antidepressants and SSRIs, may rise when modafinil is added [2]. Diphenhydramine is not named there. Separately, diphenhydramine is a potent competitive inhibitor of CYP2D6 in vitro, and in 16 healthy men it cut metoprolol clearance roughly in half in CYP2D6 extensive metabolizers, though not in poor metabolizers [8].

How long each drug lasts

Provigil reaches peak concentration 2 to 4 hours after an oral dose, and food may delay the peak by about an hour; the effective half-life is about 15 hours after multiple doses, with steady state in 2 to 4 days [2]. The Benadryl Allergy label directs 1 to 2 tablets (25 to 50 mg) every 4 to 6 hours for adults and children 12 and over, no more than 6 times in 24 hours [4]. Diphenhydramine is also sold over the counter as a nighttime sleep aid.

What the labels flag

The Benadryl Allergy Drug Facts say marked drowsiness may occur, to avoid alcoholic drinks, that alcohol, sedatives and tranquilizers may increase drowsiness, and to be careful when driving a motor vehicle or operating machinery; they also say not to use it with any other product containing diphenhydramine, even one used on skin, and that excitability may occur, especially in children [4].

On the modafinil side, pooled placebo-controlled trials in narcolepsy, OSA and shift work disorder reported insomnia in 5% of modafinil patients versus 1% on placebo, palpitation 2% versus 1%, and tachycardia 2% versus 1% [2]. The label also tells prescribers to reassess sleepiness and, if appropriate, advise patients to avoid driving [2].

Older adults and anticholinergic burden

The 2023 Beers Criteria say to avoid first-generation antihistamines, including oral diphenhydramine, in adults 65 and older (moderate quality of evidence, strong recommendation). The stated reasons are that they are highly anticholinergic, clearance falls with age, and tolerance develops when one is used as a hypnotic, with risk of confusion, dry mouth, constipation and other anticholinergic effects [5]. The criteria also say to avoid anticholinergics in dementia or cognitive impairment, in delirium or high risk of delirium, and with a history of falls or fractures unless safer alternatives are unavailable, and they note diphenhydramine may be appropriate for acute treatment of a severe allergic reaction [5]. The Provigil label says to consider lower doses and close monitoring in geriatric patients [2].

The dementia data are observational and concern strong anticholinergic drugs as a group. In a cohort of 3,434 adults 65 and older followed for a mean of 7.3 years, 797 (23.2%) developed dementia; compared with no use, the adjusted hazard ratio was 1.54 (95% CI 1.21 to 1.96) for more than 1,095 total standardized daily doses of strong anticholinergics over 10 years [9]. A separate nested case-control study of 58,769 people with dementia and 225,574 matched controls found an adjusted odds ratio of 1.49 (95% CI 1.44 to 1.54) above 1,095 total standardized daily doses, but antihistamines were not among the drug classes with a significant increase in that analysis [10]. Neither design proves cause.

Driving and the antihistamine choice

In the Iowa Driving Simulator, 40 licensed drivers aged 25 to 44 with seasonal allergic rhinitis took one dose of fexofenadine 60 mg, diphenhydramine 50 mg, alcohol at about 0.1% blood alcohol, or placebo, a week apart, then drove for an hour [6]. Diphenhydramine produced the poorest overall driving performance of the four; lane keeping was impaired after both alcohol and diphenhydramine; fexofenadine performed like placebo; and self-reported drowsiness did not predict impairment [6]. Fexofenadine was tested against placebo in that study, not against modafinil.

The modafinil label addresses driving from the other direction: wakefulness may not return to normal, so sleepiness should be reassessed and patients advised to avoid driving if appropriate [2].